Case report

Enterococcal endocarditis complicated with ruptured infected-intracranial aneurysm: With pharmacokinetic-pharmacodynamic documentation in proof of the successful antimicrobial treatment ☆

Tosiharu Urakami [a], Yohei Hamada [a], Hiroki Magarihuchi [a], Hiroki Yamakuchi [a], Yosuke Aoki [a, b, *]

[a] Division of Infectious Disease and Hospital Epidemiology, Saga University Medical Center, Japan
[b] Depatment of International Medicine, Faculty of Medicine, Saga University, Japan

ARTICLE INFO

ABSTRACT

A 74-year-old man presented with sudden onset of aphasia and apraxia. Magnetic resonance image (MRI) of the brain disclosed a left frontal hemorrhage. The concomitant low grade fever suggestive of infection was unresponsive to cefazolin 1 g q12h, and refractory to piperacillin (PIPC) 2 g q8h. Blood culture grew enterococci, establishing together with echocardiography the diagnosis of infective endocarditis. The angiography revealed cerebral hemorrhage to have resulted from the rupture of the infected intracranial aneurysm. The antimicrobial therapy was switched to ampicillin (ABPC) 2 g q4h plus gentamicin (GM) 60 mg q8h. The positive blood culture was subsequently identified *Enterococcus faecium* to which the minimum inhibitory concentration (MIC) of PIPC, and ABPC was 16 mcg/mL, and 4 mcg/mL, respectively. The peak concentration of serum ABPC was 83.1, median 50.8, and trough 25.8 mcg/mL. Thus, the percent time > MIC for ABPC was 100%, and the time > minimum bactericidal concentration (MBC) as well. On the other hand, time > MIC for PIPC, was found nearly 30% in retrospective analysis using population pharmacokinetics. The neurological deficit of the patient was completely restored to the normal status after 4-weeks' antimicrobial therapy with ABPC plus GM, then he underwent cardiac surgery for valvular replacement, where microbiological culture of the resected valve was negative. The constellation of the clinical, pharmacological and microbiological outcome in our case provides scientific evidence that the antibiotic therapy given to our case is the best available strategy as an antimicrobial treatment of severe enterococcal endocarditis complicated by disseminated lesion as infected intracranial aneurysm.

© 2014, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

1. Introduction

Infective endocarditis (IE) is a life threatening infection, manifesting systemic disease via hematogenous seeding of the infecting organism. Infected intracranial aneurysm (IIA) among others is the most serious complication of IE, with the reported incidence being 2%–5% [1,2]. Although the majority of community-acquired IE is caused by relatively limited numbers of bacteria such as staphylococci, streptococci, or enterococci, rapid determination of the antimicrobial susceptibility of the causative pathogen is of prime importance in order to put patients on the ideal antimicrobial treatment in a timely fashion. Enterococci accounting for 5–20% of IE poses a serious therapeutic concern because this pathogen is intrinsically resistant to most of the antibiotics currently available [3,4]. Although intravenous ampicillin 12g/24 h in 6 equally divided doses has been recommended as the first line regimen for the enterococcal endocarditis caused by penicillin sensitive strains [1], pharmacological principles of this recommendation have not been thoroughly explored in individual patients.

We report a case of successfully treated community-acquired enterococcal IE complicated with the infected intracranial aneurysm. The clinical and microbiological efficacies of the therapeutic

Fig. 1. Clinical course of the patient. MRI of the brain on the day 1, 8, and 28 are shown. The angiography of the brain disclosed pseudoaneurysm formation (day 8: black arrow) and echocardiography showed vegetation of the mitral valve (day 9: white arrow, LA: left atrium, LV: left ventricle). Aortic and mitral valve replacement was performed on the day 40.

strategy with penicillin antibiotics are discussed with special references to pharmacokinetic-pharmacodynamic profile.

2. Case report

A 74 year-old male patient suddenly developed aphasia and apraxia without complaining of headache or nausea. He was right-handed, previously in good health, except for the low grade fever of 2-weeks' duration prior to the presentation. His past medical history was not evident for the risk of atherosclerosis except for his age. His body temperature was 37.7 °C, pulse 92/min, and blood pressure 138/90 mmHg. The peripheral WBC count was 5800/μl, and C-reactive protein 2.5 mg/dL. The magnetic resonance imaging (MRI) of the brain showed a 2 cm hemorrhagic lesion at the periphery of the left temporo-frontal area, surrounded by minimum subarachnoid hemorrhage. The patient was admitted to the neurosurgery division and immediately put on hypertonic fluid therapy to lower the intracranial pressure. Because he had moderate grade of fever, cefazolin (CEZ) 2 g every 12 h was also started, then switched on the 5th day to piperacillin (PIPC) 2 g every 8 h for suspected bacterial infection of unspecified cause. On the 10th hospital day, he still manifested significant aphasia and fever. The follow-up brain MRI showed enlargement of the lesion, and the digital subtraction angiography (DSA) detected a 2 mm fusiform staining of the cortical branch of the precentral artery, suggesting the presence of pseudoaneurysm (Fig. 1). Upon consultation to infectious disease, two sets of blood culture were drawn while the patient was on intravenous PIPC, which yielded Gram-positive diplococcus suggestive of enterococci. Physical examination at this point of time revealed Levine III/VI systolic murmur at the apex, and diastolic murmur of the same magnitude over the midsternum. No mucocutaneous lesion suggestive of capillary damage was found. Neurological findings were not evident except for speech disturbance. The transthoracic echocardiography disclosed 10 mm vegetation of the anterior mitral leaflet and 8 mm vegetation of the right coronary cusp of the aortic valve. Since these findings were consistent with the definite diagnosis of IE [5], the cerebral hemorrhage was deemed to have resulted from the ruptured IIA.

The antimicrobial treatment was then switched from PIPC to a combination therapy of ampicillin (ABPC) 2 g every 4 h and gentamicin (GM) 60 mg every 8 h as a recommended therapy for native valve IE due to penicillin-sensitive enterococci [1]. The positive blood culture was identified as ampicillin-sensitive *Enterococcus faecium* (VITEK system; bioMerieux Japan) with the

MIC of PIPC, ABPC, and GM determined by microdilution method (IA20MIC mkII; Koden Industry) being 16 mcg/mL, 4 mcg/mL, and 8 mcg/mL, respectively.

At the time of 25th ABPC administration, steady state serum concentrations of ABPC were measured by high performance liquid chromatography (HPLC) as previously reported [6]. The peak concentration of ABPC was 83.1 mcg/mL, a value that is very close to the one reported in a recent review [7]. The trough and the mean concentration was 25.8 mcg/mL, and 50.8 mcg/mL (Table 1). The pharmacokinetic parameters of ABPC were volume of distribution (VD) 0.45 L/kg (normal value: 0.3 L/kg), total clearance 10.3 L/h (normal value: 13.0 L/h) and half-life ($T_{1/2}$) 1.8 h (normal value: 1.0 h) [8]. Hence, the percent-time of dosing interval during which serum ABPC exceeds MIC (time above MIC; T > MIC) was apparently 100%. As shown in Fig. 1, the patient's became afebrile five days after starting ABPC plus GM therapy, and the follow up blood cultures turned negative.

The patient's aphasia also showed marked improvements in response to the combined antimicrobial therapy, which was in parallel with the marked resolution of the cerebral hemorrhage (Fig. 1). The intravenous ABPC and GM were continued for 6 weeks.

Table 1
Pharmacokinetic-pharmacodynamic analyses of ampicillin (patient's PK) and piperacillin (population PK).

	Ampicillin 2 g over 30 min, q4h	Piperacillin 2 g over 30 min, q8h	
Serum concentration (mcg/mL)	Peak 83.1 Trough 25.8 Mean 50.8	Peak 223[c]	
Total clearance	10.3 liter/h[b]	11.7 liter/h[c]	[1.36 × CLcr] + 1.50 (mL/min/kg)[d]
Volume of distribution (VD)	0.45 liter/kg[b]	11.8 liter[c]	0.18 liter/kg[d]
Half-life ($T_{1/2}$)	1.8 h	1.05 h[c]	0.93 h[d]
MIC against the *E. faecium* strain[a]	4 mcg/mL	16 mcg/mL	
% time > MIC	100%	32.4%[c,e]	20.1%[d,e]

[a] Minimum inhibitory concentrations were determined by microdilution method.
[b] Serum concentrations of ABPC were determined as describes previously [6]. Total clearance, VD, and $T_{1/2}$ of ABPC were determined based on the Sawchuk–Zaske method [17] with one compartmental model equations for intermittent intravenous infusion.
[c] Median value of PK parameters from 26 subjects [15].
[d] PK parameters [16].
[e] % time > MIC for PIPC = ln [Dose/(VD × MIC)] × [$T_{1/2}$/ln (2)] × [100/dosing interval].

On follow up angiography, the aneurysm of the precentral artery was found to have almost completely disappeared, hence no need for neurosurgical procedures. Finally, because cardiac catheterization disclosed moderate to severe mitral regurgitation accompanied with increased pulmonary artery pressure, the patient underwent cardiac surgery for the aortic and mitral valve replacement. The bacterial cultures of the resected valves were negative. The patient was discharged home with oral anticonvulsant. Three months after discharge, the patient developed acute ileus, and was diagnosed as having adenocarcinoma of the ascending colon. The portal of entry of *E. faecium* that had caused infective endocarditis could have been the early mucosal lesion of the colon cancer. He finally underwent right hemicolectomy and was discharged uneventfully.

3. Discussion

The present case is unique infective endocarditis in view of that 1) community-onset native valve enterococcal endocarditis that complicated IIA is relatively uncommon [9], 2) the causative pathogen was penicillin-sensitive *E. faecium*, which remains much less common cause of IE than *E. faecalis* except for cases of vancomycin-resistant *E. faecium* [4,10], 3) neurological deficit by ruptured IIA was almost completely cured by intravenous antimicrobial treatment alone, and 4) the therapeutic efficacies of ABPC and PIPC for enterococcal endocarditis were verified with corroborating evidence of PK-PD analyses.

Enterococci represents 4.5% of younger patients and 17.5% of those 65 years or older in community-acquired IE, and the higher incidence in the latter group is partly due to the higher rates of occult gastrointestinal malignancy that could evoke translocation of enterococci into the blood stream [11], a mechanism that is considered likely in the present case in the absence of other portals of entry such as the bacteriuria or the gastrointestinal procedures. Although the incidence of aphasia due to the ruptured IIA, as seen in our patient, has been reported as low as 3% (8 among a total of 287 IIA patients) [9], since the overall mortality rate among IE patients with IIA is 60% [1], management of this serious infection needs early identification and drug susceptibility testing of the causative pathogen [2]. Nevertheless, the treatment of enterococcal endocarditis remains most difficult because of its intrinsic resistance to many classes of antimicrobials. Especially *E. faecium* is in the vast majority of instances far less sensitive to penicillins than *E. faecalis* due to the constitutive presence of penicillin-binding protein (PBP) 5, the affinity of which to penicillin is lower than that of *E. faecalis* PBP 5 [12].

Fortunately in our patient the MIC of ABPC, a drug of choice for susceptible enterococci, against the *E. faecium* strain was 4 mcg/mL, which is sensitive by the definition of Clinical Laboratory Standard Institutes [13]. That the PIPC MIC was 16 mcg/mL is in accordance with the differential penicillin susceptibility inherent to *E. faecium* [12].

The trough, mean, and peak concentration of ABPC at steady state was approximately 6 ×, 12 ×, and 20 × MIC, respectively. Assuming that minimum bactericidal concentration (MBC) of beta-lactam is usually within 2—4-fold of MIC [14], time above MBC had also likely reached to 100% during the course of ABPC treatment. Given that successful antimicrobial treatment of enterococcal IE requires the trough level above the MIC [11], the serum ABPC concentrations observed in this patient were within the ideal range, even though the successful outcome is partly attributed to the synergistic effect of GM with ABPC against enterococci [1]. Blood concentration measurements were done once only. However, pharmacokinetic parameters seem to have been settled because there were no significant changes in CL and VD manifestations (e.g.,

serum creatinine, urea nitrogen and body weight) during ABPC administration.

In another patient with renal insufficiency who developed IE caused by *E, faecalis*, we analyzed PK-PD profile of ABPC intravenously administered 2 g as a bolus infusion every 12 h. Based on the measurement of serum concentrations by HPLC in the reference laboratory (Meiji Seika Pharma Co., Ltd., Japan), the following pharmacokinetic parameters of ABPC were noted: peak concentration 106 mcg/mL, trough concentration 20.7 mcg/mL, VD 0.44 L/kg, total clearance 3.19 L/h, and $T_{1/2}$ 5.1 h. Again, increase in VD was remarkable as was in the present case. These findings together with the present case may indicate that the increased VD could be due to the systemic fluid shifts from the intravascular compartment to the interstitial space resulting from vascular hyperpermeability that accompanied sepsis. Accordingly, increased VD led to decrease in the serum concentrations of ABPC. Thus careful attention should be paid to the alterations in pharmacokinetic parameters of beta-lactam in IE patients because suboptimal serum concentration of the antibiotics will easily lead to therapeutic failure.

Retrospective PK-PD analyses of PIPC treatment in this patient using population PK parameters from the two different resources [15,16] with the use of the Sawchuk—Zaske equation [17] calculated that time > MIC of PIPC 2 g every 8 h was 20—30% (Table 1). That the blood culture grew ampicillin-sensitive *E. faecium* while the patient was on intravenous PIPC convinces that T > MIC of penicillin to this extent is not sufficient enough to exert bactericidal effect [18].

Although in a rabbit model of endocarditis caused by *Echerichia coli*, ceftriaxone concentrations in the vegetation of 200 × MBC was reportedly necessary for significant killing of bacteria [19], the ABPC concentration observed in our patient (10—20-times MIC) was probably high enough to eradicate ampicillin-sensitive *E. faecium* from the cardiac vegetation because the surgical specimen was microbiologically negative. This bacteriological finding of resected valves denoted that our antimicrobial treatment was proper [20]. In conclusion, the present case proves that the widely recommended dosing regimen of ABPC in the treatment of penicillin-sensitive enterococcal bacteremia including endocarditis is capable of achieving clinical cure as well as microbiological eradication.

Conflict of interest

None.

References

[1] Baddour LM, Wilson WR, Bayer AS, Fowler Jr VG, Bolger AF, Levison ME, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, and the councils on clinical cardiology, stroke, and cardiovascular surgery and anesthesia, American heart association: endorsed by the infectious diseases society of America. Circulation 2005;111: e394—434.

[2] Peters PJ, Harrison T, Lennox JL. A dangerous dilemma: management of infectious intracranial aneurysms complicating endocarditis. Lancet Infect Dis 2006;6:742—8.

[3] Megran DW. Enterococcal endocarditis. Clin Infect Dis 1992;15:63—71.

[4] Gilmore MS, Coburn PS, Nallapareddy SR, Murray BE. Enterococcal virulence. In: Gilmore MS, Clewell DB, Courvalin P, editors. The enterococci:pathogenesis, molecular biology, and antibiotic resistance. Washington DC: ASM Press; 2002. p. 301—54.

[5] Li JS, Sexton DJ, Mick N, Nettles R, Fowler Jr VG, Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000;30:633—8.

[6] Aoki Y, Urakami T, Magarifuchi H, Nagasawa Z, Nagata M, Fukuoka M. The importance of pharmacokinetic consultation of cefepime treatment for *Pseudomonas aeruginosa* bacteremia: a case report of severe thermal burn injury. J Infect Chemother 2011;17:407—11.

[7] Betrosian AP, Douzinas EE. Ampicillin-sulbactam: an update on the use of parenteral and oral forms in bacterial infections. Expert Opin Drug Metab Toxicol 2009;5:1099—112.

[8] Pharmacokinetic drug data. In: Speight Trevor M, Holford Nicholas HG, editors. Avery's drug treatment 4th edition. New Jersey: Wiley-Blackwell; 1997. p. 1639—64.

[9] Ducruet AF, Hickman ZL, Zacharia BE, Narula R, Grobelny BT, Gorski J, et al. Intracranial infectious aneurysms: a comprehensive review. Neurosurg Rev 2010;33:37—46.

[10] Mundy LM, Sahm DF, Gilmore M. Relationships between enterococcal virulence and antimicrobial resistance. Clin Microbiol Rev 2000;13:513—22.

[11] Durante-Mangoni E, Bradley S, Selton-Suty C, Tripodi MF, Barsic B, Bouza E, et al. Current features of infective endocarditis in elderly patients: results of the international collaboration on endocarditis prospective cohort study. Arch Intern Med 2008;168:2095—103.

[12] Mainardi JL. β-lactams and enteroccoi. In: Courvalin P, Leclercq R, Rice LB, editors. Antibiogram. Portland: ASM Press; 2010. p. 127—33.

[13] Wayne PA. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. CLSI document M100—S20. Clinical and Laboratory Standards Institute; 2010.

[14] Hessen MT, Kaye D. Principles of selection and use of antibacterial agents. In vitro activity and pharmacology. Infect Dis Clin North Am 2000;14: 265—79.

[15] Bulitta JB, Duffull SB, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano GL, et al. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2007;51:2497—507.

[16] Thummel Kenneth E, Shen Danny D. Design and optimization of dosage regimens: pharmacokinetic data. In: Sanford Goodman Louis, Limbird Lee E, Milinoff Perry B, Ruddon Raymond W, editors. Alfred Goodman Gilman Goodman & Gilman's the pharmacological basis of therapeutics 9th edition. New York: McGraw-Hill; 1996. p.1917—2024.

[17] Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm 1976;4:183—95.

[18] Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1—10.

[19] Joly V, Pangon B, Vallois JM, Abel L, Brion N, Bure A, et al. Value of antibiotic levels in serum and cardiac vegetations for predicting antibacterial effect of ceftriaxone in experimental *Escherichia coli* endocarditis. Antimicrob Agents Chemother 1987;31:1632—9.

[20] Stone JR, Basso C, Baandrup UT, Bruneval P, Butany J, Gallagher PJ, et al. Recommendations for processing cardiovascular surgical pathology specimens: a consensus statement from the standards and definitions committee of the society for cardiovascular pathology and the association for European cardiovascular pathology. Cardiovasc Pathol 2012;21:2—16.